Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

212 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma.
Bonnetain F, Dahan L, Maillard E, Ychou M, Mitry E, Hammel P, Legoux JL, Rougier P, Bedenne L, Seitz JF. Bonnetain F, et al. Among authors: mitry e. Eur J Cancer. 2010 Oct;46(15):2753-62. doi: 10.1016/j.ejca.2010.07.023. Epub 2010 Aug 17. Eur J Cancer. 2010. PMID: 20724140 Clinical Trial.
Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial)--a phase II non-randomised trial.
Ducreux M, Dahan L, Smith D, O'Toole D, Lepère C, Dromain C, Vilgrain V, Baudin E, Lombard-Bohas C, Scoazec JY, Seitz JF, Bitoun L, Koné S, Mitry E. Ducreux M, et al. Among authors: mitry e. Eur J Cancer. 2014 Dec;50(18):3098-106. doi: 10.1016/j.ejca.2014.10.002. Epub 2014 Oct 27. Eur J Cancer. 2014. PMID: 25454412 Clinical Trial.
Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology.
Bonnetain F, Bouché O, Conroy T, Arveux P, Raoul JL, Giovannini M, Etienne PL, Mitry E, Seitz JF, Rougier P, Girault C, Bedenne L; FFCD (Fédération Francophone de Cancérologie Digestive). Bonnetain F, et al. Among authors: mitry e. Gastroenterol Clin Biol. 2005 Nov;29(11):1113-24. doi: 10.1016/s0399-8320(05)82175-x. Gastroenterol Clin Biol. 2005. PMID: 16505756 Free article. Clinical Trial.
Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).
Dahan L, Bonnetain F, Ychou M, Mitry E, Gasmi M, Raoul JL, Cattan S, Phelip JM, Hammel P, Chauffert B, Michel P, Legoux JL, Rougier P, Bedenne L, Seitz JF; Fédération Francophone de Cancérologie Digestive. Dahan L, et al. Among authors: mitry e. Gut. 2010 Nov;59(11):1527-34. doi: 10.1136/gut.2010.216135. Gut. 2010. PMID: 20947887 Free PMC article. Clinical Trial.
Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort.
Pernot S, Mitry E, Samalin E, Dahan L, Dalban C, Ychou M, Seitz JF, Turki H, Mazard T, Zaanan A, Lepère C, Vaillant JN, Landi B, Rougier P, Taieb J. Pernot S, et al. Among authors: mitry e. Gastric Cancer. 2014 Apr;17(2):341-7. doi: 10.1007/s10120-013-0266-6. Epub 2013 Jun 6. Gastric Cancer. 2014. PMID: 23739764
Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials).
Bonnetain F, Bonsing B, Conroy T, Dousseau A, Glimelius B, Haustermans K, Lacaine F, Van Laethem JL, Aparicio T, Aust D, Bassi C, Berger V, Chamorey E, Chibaudel B, Dahan L, De Gramont A, Delpero JR, Dervenis C, Ducreux M, Gal J, Gerber E, Ghaneh P, Hammel P, Hendlisz A, Jooste V, Labianca R, Latouche A, Lutz M, Macarulla T, Malka D, Mauer M, Mitry E, Neoptolemos J, Pessaux P, Sauvanet A, Tabernero J, Taieb J, van Tienhoven G, Gourgou-Bourgade S, Bellera C, Mathoulin-Pélissier S, Collette L. Bonnetain F, et al. Among authors: mitry e. Eur J Cancer. 2014 Nov;50(17):2983-93. doi: 10.1016/j.ejca.2014.07.011. Epub 2014 Sep 22. Eur J Cancer. 2014. PMID: 25256896 Review.
High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study.
Manfredi S, Bouché O, Rougier P, Dahan L, Loriot MA, Aparicio T, Etienne PL, Lafargue JP, Lécaille C, Legoux JL, Le Malicot K, Maillard E, Lecomte T, Khemissa F, Breysacher G, Michel P, Mitry E, Bedenne L. Manfredi S, et al. Among authors: mitry e. Mol Cancer Ther. 2015 Dec;14(12):2782-8. doi: 10.1158/1535-7163.MCT-15-0293. Epub 2015 Oct 22. Mol Cancer Ther. 2015. PMID: 26494856 Clinical Trial.
Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients.
Aparicio T, Gargot D, Teillet L, Maillard E, Genet D, Cretin J, Locher C, Bouché O, Breysacher G, Seitz JF, Gasmi M, Stefani L, Ramdani M, Lecomte T, Auby D, Faroux R, Bachet JB, Lepère C, Khemissa F, Sobhani I, Boulat O, Mitry E, Jouve JL; FFCD 2001-02 investigators. Aparicio T, et al. Among authors: mitry e. Eur J Cancer. 2017 Mar;74:98-108. doi: 10.1016/j.ejca.2016.09.029. Epub 2016 Nov 5. Eur J Cancer. 2017. PMID: 27825697 Clinical Trial.
Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02).
Aparicio T, Lavau-Denes S, Phelip JM, Maillard E, Jouve JL, Gargot D, Gasmi M, Locher C, Adhoute X, Michel P, Khemissa F, Lecomte T, Provençal J, Breysacher G, Legoux JL, Lepère C, Charneau J, Cretin J, Chone L, Azzedine A, Bouché O, Sobhani I, Bedenne L, Mitry E; FFCD investigators. Aparicio T, et al. Among authors: mitry e. Ann Oncol. 2016 Jan;27(1):121-7. doi: 10.1093/annonc/mdv491. Epub 2015 Oct 20. Ann Oncol. 2016. PMID: 26487578 Free article. Clinical Trial.
212 results